SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
3.850
+0.040 (1.05%)
At close: Jun 26, 2026, 4:00 PM EDT
3.920
+0.070 (1.82%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Company Description
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.
The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections.
The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | May 2, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 18 |
| CEO | David Angulo |
Contact Details
Address: 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 United States | |
| Phone | 201 884 5485 |
| Website | scynexis.com |
Stock Details
| Ticker Symbol | SCYX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178253 |
| CUSIP Number | 81134L208 |
| ISIN Number | US8112922005 |
| Employer ID | 56-2181648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Gonzalez Angulo M.D. | Chief Executive Officer, President and Director |
| Ivor Macleod CPA, M.B.A. | Chief Financial Officer |
| Scott Sukenick J.D. | Chief Legal Officer and Corporate Secretary |
| Daniella Gigante | Vice President of Human Resources and Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2026 | 8-K | Current Report |
| May 29, 2026 | 8-K | Current Report |
| May 22, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | 10-Q | Quarterly Report |
| May 8, 2026 | EFFECT | Notice of Effectiveness |
| May 8, 2026 | 424B3 | Prospectus |
| May 6, 2026 | UPLOAD | Filing |
| May 1, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |